Torrent Pharma's bid for Zentiva could be a step too far

Torrent Pharma seeks to boost its European footprint with the largest outbound transaction in India's pharmaceutical history. But it may not pay off for its shareholders.
March 15, 2018

On the face of it, Torrent Pharmaceutical's $2.5 billion bid for Sanofi's generic drug subsidiary Zentiva looks like a great deal for India’s 11th largest pharma firm by market cap. Similar product portfolios, new market penetration in 50 countries home to a billion people and an established pharma player in Eastern Europe all points to a sure winner for Torrent.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Related Articles

Srini Kannan to return to Citi in India

Citi Commercial Bank in India has appointed Kannan as head of digital, technology, communication, business & professional services and industrials; he will join in December and has worked at JP Morgan for over 15 years.
October 15, 2025